In Vitro and In Vivo Activities of Arachidonic Acid against Schistosoma mansoni and Schistosoma haematobium
- 1 August 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (8) , 3383-3389
Abstract
The development of arachidonic acid (ARA) for treatment of schistosomiasis is an entirely novel approach based on a breakthrough discovery in schistosome biology revealing that activation of parasite tegument-bound neutral sphingomyelinase (nSMase) by unsaturated fatty acids, such as ARA, induces exposure of parasite surface membrane antigens to antibody binding and eventual attrition of developing schistosomula and adult worms. Here, we demonstrate that 5 mM ARA leads to irreversible killing of ex vivo 1-, 3-, 4-, 5-, and 6-week-old Schistosoma mansoni and 9-, 10-, and 12-week-old Schistosoma haematobium worms within 3 to 4 h, depending on the parasite age, even when the worms were maintained in up to 50% fetal calf serum. ARA-mediated worm attrition was prevented by nSMase inhibitors, such as CaCl 2 and GW4869. Scanning and transmission electron microscopy revealed that ARA-mediated worm killing was associated with spine destruction, membrane blebbing, and disorganization of the apical membrane structure. ARA-mediated S. mansoni and S. haematobium worm attrition was reproduced in vivo in a series of 6 independent experiments using BALB/c or C57BL/6 mice, indicating that ARA in a pure form (Sigma) or included in infant formula (Nestle) consistently led to 40 to 80% decrease in the total worm burden. Arachidonic acid is already marketed for human use in the United States and Canada for proper development of newborns and muscle growth of athletes; thus, ARA has potential as a safe and cost-effective addition to antischistosomal therapy.Keywords
This publication has 36 references indexed in Scilit:
- Activity of Artemether and Mefloquine against Juvenile and Adult Schistosoma mansoni in Athymic and Immunocompetent NMRI MiceThe American Journal of Tropical Medicine and Hygiene, 2010
- Transbilayer (flip‐flop) lipid motion and lipid scrambling in membranesFEBS Letters, 2009
- Praziquantel Affects the Regulatory Myosin Light Chain of Schistosoma mansoniAntimicrobial Agents and Chemotherapy, 2009
- Mefloquine—An Aminoalcohol with Promising Antischistosomal Properties in MicePLOS Neglected Tropical Diseases, 2009
- Identification of oxadiazoles as new drug leads for the control of schistosomiasisNature Medicine, 2008
- Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at riskThe Lancet Infectious Diseases, 2006
- Biochemical Properties of Mammalian Neutral Sphingomyelinase2 and Its Role in Sphingolipid MetabolismJournal of Biological Chemistry, 2003
- Inhibition of Tumor Necrosis Factor-induced Cell Death in MCF7 by a Novel Inhibitor of Neutral SphingomyelinaseJournal of Biological Chemistry, 2002
- De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, PathwayJournal of Biological Chemistry, 2002
- Effect of artemether against Schistosoma haematobium in experimentally infected hamstersInternational Journal for Parasitology, 2000